MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
MacroGenics (MGNX) PT Raised to $40 at SunTrust Robinson Humphrey
February 6, 2019 1:30 PM ESTSunTrust Robinson Humphrey analyst Peter Lawson raised the price target on MacroGenics (NASDAQ: MGNX) to $40.00 (from $28.00) while maintaining a Buy rating.
... MoreMacrogenics (MGNX) Adds to Gains, Up 140%
February 6, 2019 9:06 AM ESTMacrogenics (NASDAQ: MGNX) Adds to Gains, Up 140%
... MoreMacrogenics (MGNX) Could Trade to $2B+ Valuation - Evercore ISI
February 6, 2019 8:47 AM ESTEvercore ISI analyst Umer Raffat said a $2 billion+ valuation for Macrogenics (NASDAQ: MGNX) is 'very likely' as SOPHIA hits.
Macrogenics (MGNX) Climbs 100% After Reporting Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
February 6, 2019 7:55 AM ESTMacrogenics (NASDAQ: MGNX) Climbs 100% After Reporting Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
... More